HIGHTIDE-B(02511.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
HIGHTIDE-B
02511.HK
HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis (MASH); in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as in phase II clinical trial to treat primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTD1804 that is in preclinical trial to treat obesity; HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases; HTF1057 a preclinical-stage a drug candidate for the treatment of neurodegenerative diseases; HTF1037 a preclinical-stage for the treatment of obesity and comorbidities; and HTD2802 that is in preclinical trial for treating inflammatory bowel disease. HighTide Therapeutics, Inc.
1.386 T
02511.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    HIGHTIDE (2511) presents kidney benefit data for HTD1801 at the American Society of Nephrology Annual Meeting

    HIGHTIDE showcased the renal benefit data of HTD1801 in patients with mild renal impairment at the 58th Annual Meeting of the American Society of Nephrology. Clinical results indicate that HTD1801 has the potential to improve eGFR changes in chronic kidney disease (CKD) patients and restore kidney function, bringing substantial health benefits to patients. HTD1801 is a globally innovative new molecular entity focused on cardiorenal metabolic system diseases (CKM)

    etnet·
    HK
    02511
    +1.43%
    etnet·
    HK
    02511
    +1.43%

    HIGHTIDE-B: The world's first anti-inflammatory metabolic regulator HTD1801 has completed Phase III clinical research for Type 2 diabetes, demonstrating sustained comprehensive benefits and safety advantages over 52 weeks

    HIGHTIDE-B announced that its anti-inflammatory metabolic regulator HTD1801 has successfully completed Phase III clinical trials in patients with type 2 diabetes, demonstrating efficacy and safety advantages over 52 weeks. The study results show that HTD1801 is effective in reducing blood lipids and inflammatory markers, and long-term treatment is safe. The company plans to submit a new drug application for HTD1801 to the National Medical Products Administration within this year

    Zhitong·
    HK
    02511
    +1.43%
    Zhitong·
    HK
    02511
    +1.43%

    Understanding the Market | HIGHTIDE-B rose nearly 8% as losses narrowed by 42.96% year-on-year in the first half

    HIGHTIDE-B rose nearly 8%, as of the time of writing, up 7.94%, priced at HKD 3.4, with a transaction volume of HKD 5.8183 million. In terms of news, HIGHTIDE-B released its interim results for the six months ending June 30, 2025, reporting other income of RMB 10.542 million, a year-on-year decrease of 69.96%; a loss attributable to shareholders of RMB 120 million, a year-on-year narrowing of 42.96%; and a basic loss per share of RMB 0.27. The announcement stated that the decrease in other income was mainly due to a reduction in government subsidies of approximately RMB 19.1 million. The company's core product HTD1801 is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system. Currently, HTD1801 is being developed globally for the treatment of CKM-related diseases, including type 2 diabetes (T2DM), metabolic-associated fatty liver disease (MASH), chronic kidney disease (CKD), obesity, primary sclerosing cholangitis (PSC), and severe hypertriglyceridemia (SHTG)

    Zhitong·
    HK
    02511
    +1.43%
    Zhitong·
    HK
    02511
    +1.43%

    HIGHTIDE-B released its interim results, with a loss attributable to shareholders of 120 million yuan, narrowing by 42.96% year-on-year

    According to the Zhitong Finance APP, HIGHTIDE-B announced its interim results for the six months ending June 30, 2025, with other income of RMB 10.542 million, a year-on-year decrease of 69.96%; the loss attributable to shareholders was RMB 120 million, a year-on-year narrowing of 42.96%; basic loss per share was RMB 0.27. The announcement stated that the decrease in other income was mainly due to a reduction in government subsidies of approximately RMB 19.1 million

    Zhitong·
    HK
    02511
    +1.43%
    Zhitong·
    HK
    02511
    +1.43%

    HIGHTIDE-B once surged 10% in collaboration with the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences on research projects

    HIGHTIDE-B surged 10% during today's trading to HKD 3.39, with a year-to-date increase of 1.67 times. The company is collaborating with the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences to assess the therapeutic potential of its core product HTD1801 for diabetes with chronic kidney disease, advancing clinical evaluation, expanding its product pipeline, and supporting innovation and development in the field of metabolic disease treatment

    Zhitong·
    HK
    02511
    +1.43%
    Zhitong·
    HK
    02511
    +1.43%
    © 2026 Longbridge｜Disclaimer